Welcome to our dedicated page for Corvus Pharmaceuticals SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Corvus Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Corvus Pharmaceuticals's regulatory disclosures and financial reporting.
Corvus Pharmaceuticals, Inc. is holding a fully virtual annual meeting of stockholders on June 11, 2026 at 1:00 p.m. Pacific Time. Holders of 84,090,424 common shares as of April 16, 2026 can vote online, by phone or by mail on three main proposals.
Stockholders will vote on electing two Class I directors (Richard A. Miller and Linda S. Grais), ratifying PricewaterhouseCoopers LLP as independent auditor for 2026, and approving on a non-binding advisory basis the compensation of named executive officers. The board recommends votes in favor of all three proposals.
Corvus Pharmaceuticals appointed Andrew C. Chan, M.D., Ph.D. to its Board of Directors, effective April 23, 2026. He will serve as a Class II director with a term expiring at the 2027 annual stockholder meeting and will also join the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation program, Dr. Chan will receive a $35,000 annual cash retainer for Board service and an initial stock option for 30,000 shares of common stock under the 2016 Equity Incentive Award Plan, plus $4,000 annually for Nominating Committee service. On the same date, longtime director Scott Morrison notified the company of his resignation from the Board, effective April 23, 2026.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G for Corvus Pharmaceuticals Inc, reporting 0 shares beneficially owned of Common Stock and 0% ownership as stated in the amendment dated 03/13/2026. The filing states Vanguard reorganized internally on January 12, 2026, and certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
The signature block shows the filing was signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026.
Corvus Pharmaceuticals, Inc. established an amended at-the-market equity program to sell up to $200,000,000 of common stock through Jefferies LLC as sales agent under a newly filed automatic shelf registration on Form S-3.
The new Amended and Restated Open Market Sale Agreement replaces a prior $100,000,000 arrangement under which no shares had been sold as of March 13, 2026. Jefferies will use commercially reasonable efforts to place shares by various permitted methods and may earn a commission of up to 3.0% of the gross sales price per share.
Registers up to $200,000,000 of common stock for sale in an amended at-the-market program. Corvus Pharmaceuticals amended its open market sales agreement with Jefferies to increase the maximum aggregate offering price from $100,000,000 to $200,000,000, with Jefferies serving as sales agent. The company has not sold shares under the prior agreement and suspended the prior program effective January 20, 2026. Sales, if any, will be made from time to time on the Nasdaq Global Market under an at the market plan; Jefferies may receive up to 3.0% of gross proceeds as compensation. The prospectus cites a March 11, 2026 last reported sale price of $16.90 and states shares outstanding of 74,696,629 as of December 31, 2025.
Corvus Pharmaceuticals, Inc. has filed a Form S-3 shelf registration to allow the company to offer from time to time common stock, preferred stock, debt securities, warrants and units under a single shelf prospectus. The shelf permits multiple offerings after the registration statement is effective.
The prospectus notes the company’s common stock trades on Nasdaq under the symbol CRVS and cites a March 11, 2026 last reported sale price of $16.90 per share. The prospectus also discloses capital structure details (authorized common and preferred shares) and that, as of December 31, 2025, Pre-Funded Warrants to purchase up to 8,275,913 shares were outstanding.
Corvus Pharmaceuticals files its Annual Report describing a late-stage immunology and oncology pipeline built around T‑cell modulation. The lead drug, soquelitinib, is in a registrational Phase 3 trial for relapsed peripheral T‑cell lymphoma and a Phase 2 trial for moderate‑to‑severe atopic dermatitis.
Earlier Phase 1 work in atopic dermatitis showed meaningful EASI score reductions versus placebo and favorable safety. Corvus is also advancing ciforadenant in kidney cancer and mupadolimab for future oncology and infectious disease uses, supported by a broad global patent estate.
As of June 30, 2025, non‑affiliate common stock market value was about $251.9 million, and as of March 12, 2026, 83,992,407 common shares were outstanding.
Corvus Pharmaceuticals provided a business update and reported fourth quarter and full year 2025 results, emphasizing progress for its lead ITK inhibitor soquelitinib and a strengthened balance sheet.
In atopic dermatitis, cohort 4 of the Phase 1 trial showed encouraging efficacy, with 75% of soquelitinib patients achieving EASI 75, 25% achieving EASI 90 and 33% reaching IGA 0/1, compared with 20%, 0% and 0% for placebo, alongside a clean safety profile and no dose modifications or treatment-related discontinuations across more than 14,000 treatment days. Corvus has initiated a Phase 2 atopic dermatitis trial and continues enrolling a registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, where soquelitinib holds Orphan Drug and Fast Track designations.
As of December 31, 2025, Corvus held $56.8 million in cash, cash equivalents and marketable securities, not including approximately $189.4 million in net proceeds from a January 23, 2026 public offering, which it expects will fund operations into the second quarter of 2028. Research and development expenses rose to $33.7 million in 2025 from $19.4 million in 2024 as clinical programs expanded, and net loss narrowed to $15.3 million from $62.3 million, partly reflecting prior-period warrant liability fair value changes.
Corvus Pharmaceuticals, Inc. insider ownership is detailed in an amended Schedule 13G filing. As of December 31, 2025, Dr. Richard A. Miller is reported as the beneficial owner of 6,085,922 shares of common stock, or 7.8% of the class, based on 74,681,872 shares outstanding as of November 4, 2025.
Dr. Miller’s position includes 1,136,707 shares held directly, 1,188,103 shares held through the Miller-Horning Family Trust, and 3,761,112 shares underlying stock options that are vested or vest within 60 days of December 31, 2025. The Miller-Horning Family Trust and Dr. Sandra J. Horning each beneficially own 1,188,103 shares, representing 1.6% of the common stock.
Adams Street investment funds updated their ownership disclosure in Corvus Pharmaceuticals after a major stock offering. Adams Street Partners and affiliated funds now beneficially own 3,275,616 shares of Corvus common stock, representing 3.9% of the 83,767,650 shares outstanding as of January 23, 2026.
The change in percentage is reported as arising solely from Corvus’ underwritten public offering, in which the company sold 7,900,677 shares at $22.15 per share and an additional 1,185,101 shares through the underwriters’ option. The Adams Street reporting group states it has not traded Corvus shares in the past 60 days.